Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

job cuts

- PMLiVE

Sanofi expands immunology pipeline by acquiring Dren’s bispecific for $600m upfront

The candidate has shown potential in treating B-cell mediated autoimmune diseases

- PMLiVE

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

The company is expecting to file for the first regulatory approval of the drug next year

- PMLiVE

Novo Nordisk and Gensaic enter cardiometabolic disease partnership worth $354m

The companies will use Gensaic’s protein design technology to discover protein ligands

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

Sanofi and Regeneron’s Dupixent granted FDA priority review for bullous pemphigoid

Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease

- PMLiVE

Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

- PMLiVE

Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma

An estimated 5,900 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

- PMLiVE

Sanofi’s Sarclisa granted EC approval to treat newly diagnosed multiple myeloma

Approximately 46,000 cases of the disease are expected to be diagnosed in Europe in 2025

- PMLiVE

Novo shares promising results for high-dose semaglutide in late-stage obesity study

The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

- PMLiVE

Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases

The partners are aiming to develop new drugs for type 2 diabetes, obesity and cardiovascular disease

- PMLiVE

Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links